264 related articles for article (PubMed ID: 18987434)
1. Molecular determinants of hERG channel block by terfenadine and cisapride.
Kamiya K; Niwa R; Morishima M; Honjo H; Sanguinetti MC
J Pharmacol Sci; 2008 Nov; 108(3):301-7. PubMed ID: 18987434
[TBL] [Abstract][Full Text] [Related]
2. Structural requirements of human ether-a-go-go-related gene channels for block by bupivacaine.
Siebrands CC; Friederich P
Anesthesiology; 2007 Mar; 106(3):523-31. PubMed ID: 17325511
[TBL] [Abstract][Full Text] [Related]
3. Open channel block of HERG K(+) channels by vesnarinone.
Kamiya K; Mitcheson JS; Yasui K; Kodama I; Sanguinetti MC
Mol Pharmacol; 2001 Aug; 60(2):244-53. PubMed ID: 11455010
[TBL] [Abstract][Full Text] [Related]
4. Mutational analysis of block and facilitation of HERG current by a class III anti-arrhythmic agent, nifekalant.
Hosaka Y; Iwata M; Kamiya N; Yamada M; Kinoshita K; Fukunishi Y; Tsujimae K; Hibino H; Aizawa Y; Inanobe A; Nakamura H; Kurachi Y
Channels (Austin); 2007; 1(3):198-208. PubMed ID: 18690032
[TBL] [Abstract][Full Text] [Related]
5. A structural basis for drug-induced long QT syndrome.
Mitcheson JS; Chen J; Lin M; Culberson C; Sanguinetti MC
Proc Natl Acad Sci U S A; 2000 Oct; 97(22):12329-33. PubMed ID: 11005845
[TBL] [Abstract][Full Text] [Related]
6. Position of aromatic residues in the S6 domain, not inactivation, dictates cisapride sensitivity of HERG and eag potassium channels.
Chen J; Seebohm G; Sanguinetti MC
Proc Natl Acad Sci U S A; 2002 Sep; 99(19):12461-6. PubMed ID: 12209010
[TBL] [Abstract][Full Text] [Related]
7. Structural determinants of HERG channel block by clofilium and ibutilide.
Perry M; de Groot MJ; Helliwell R; Leishman D; Tristani-Firouzi M; Sanguinetti MC; Mitcheson J
Mol Pharmacol; 2004 Aug; 66(2):240-9. PubMed ID: 15266014
[TBL] [Abstract][Full Text] [Related]
8. Molecular determinants of cocaine block of human ether-á-go-go-related gene potassium channels.
Guo J; Gang H; Zhang S
J Pharmacol Exp Ther; 2006 May; 317(2):865-74. PubMed ID: 16397089
[TBL] [Abstract][Full Text] [Related]
9. A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG.
Rampe D; Roy ML; Dennis A; Brown AM
FEBS Lett; 1997 Nov; 417(1):28-32. PubMed ID: 9395068
[TBL] [Abstract][Full Text] [Related]
10. Block of wild-type and inactivation-deficient human ether-a-go-go-related gene K+ channels by halofantrine.
Sánchez-Chapula JA; Navarro-Polanco RA; Sanguinetti MC
Naunyn Schmiedebergs Arch Pharmacol; 2004 Dec; 370(6):484-91. PubMed ID: 15558243
[TBL] [Abstract][Full Text] [Related]
11. Interactions at human ether-à-go-go-related gene channels.
Friemel A; Zünkler BJ
Toxicol Sci; 2010 Apr; 114(2):346-55. PubMed ID: 20071423
[TBL] [Abstract][Full Text] [Related]
12. Molecular determinants of HERG channel block.
Kamiya K; Niwa R; Mitcheson JS; Sanguinetti MC
Mol Pharmacol; 2006 May; 69(5):1709-16. PubMed ID: 16474003
[TBL] [Abstract][Full Text] [Related]
13. Voltage-dependent profile of human ether-a-go-go-related gene channel block is influenced by a single residue in the S6 transmembrane domain.
Sănchez-Chapula JA; Ferrer T; Navarro-Polanco RA; Sanguinetti MC
Mol Pharmacol; 2003 May; 63(5):1051-8. PubMed ID: 12695533
[TBL] [Abstract][Full Text] [Related]
14. Blockage of the HERG human cardiac K+ channel by the gastrointestinal prokinetic agent cisapride.
Mohammad S; Zhou Z; Gong Q; January CT
Am J Physiol; 1997 Nov; 273(5):H2534-8. PubMed ID: 9374794
[TBL] [Abstract][Full Text] [Related]
15. Investigating dynamic protocol-dependence of hERG potassium channel inhibition at 37 degrees C: Cisapride versus dofetilide.
Milnes JT; Witchel HJ; Leaney JL; Leishman DJ; Hancox JC
J Pharmacol Toxicol Methods; 2010; 61(2):178-91. PubMed ID: 20172036
[TBL] [Abstract][Full Text] [Related]
16. Blockade of HERG K+ channel by an antihistamine drug brompheniramine requires the channel binding within the S6 residue Y652 and F656.
Park SJ; Kim KS; Kim EJ
J Appl Toxicol; 2008 Mar; 28(2):104-11. PubMed ID: 17516459
[TBL] [Abstract][Full Text] [Related]
17. The molecular determinants of R-roscovitine block of hERG channels.
Cernuda B; Fernandes CT; Allam SM; Orzillo M; Suppa G; Chia Chang Z; Athanasopoulos D; Buraei Z
PLoS One; 2019; 14(9):e0217733. PubMed ID: 31479461
[TBL] [Abstract][Full Text] [Related]
18. Hydroxypropyl beta-cyclodextrins: a misleading vehicle for the in vitro hERG current assay.
Mikhail A; Fischer C; Patel A; Long MA; Limberis JT; Martin RL; Cox BF; Gintant GA; Su Z
J Cardiovasc Pharmacol; 2007 May; 49(5):269-74. PubMed ID: 17513944
[TBL] [Abstract][Full Text] [Related]
19. New potential binding determinant for hERG channel inhibitors.
Saxena P; Zangerl-Plessl EM; Linder T; Windisch A; Hohaus A; Timin E; Hering S; Stary-Weinzinger A
Sci Rep; 2016 Apr; 6():24182. PubMed ID: 27067805
[TBL] [Abstract][Full Text] [Related]
20. Physicochemical features of the HERG channel drug binding site.
Fernandez D; Ghanta A; Kauffman GW; Sanguinetti MC
J Biol Chem; 2004 Mar; 279(11):10120-7. PubMed ID: 14699101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
